HERCULES, Calif., July 07, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the ...
HERCULES, Calif., August 01, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that ...
HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO and BIO.B), a life sciences company with a market capitalization of $6.8 billion and strong financial health according to InvestingPro data, ...
Bio-Rad Laboratories has received FDA clearance for two digital PCR products designed to monitor patients’ molecular responses to tyrosine kinase inhibitor treatments in chronic myeloid leukemia. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback